Skip to main content

New Drug Approvals 2011 - Pt. XXX - Aflibercept (EyleaTM)


ATC code (partial): S01LA

On November 18th 2011, the FDA approved Aflibercept (trade name: Eylea; Research Code: AVE-0005,  also known as VEGF Trap), a recombinant fusion protein indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD).

AMD is an eye condition which usually occurs in older patients and affects the macula area of the retina, causing loss of vision and eventually blindness. In particular, wet AMD is characterised by an abnormal growth of new blood vessels (neovascularisation) behind the retina. This originates from an abnormal activation of angiogenesis, by the vascular endothelial growth factor-A (VEGF-A; ChEMBL: CHEMBL1783; Uniprot: P15692) and the placenta growth factor (PlGF; ChEMBL: CHEMBL1697671; Uniprot: P49763), of the vascular endothelial growth factor receptors VEGFR-1 (ChEMBL: CHEMBL1868; Uniprot: P17948) and VEGFR-2 (ChEMBL: CHEMBL279; Uniprot: P35968), two receptor tyrosine kinases present on the surface of endothelial cells. This leads to abnormal increased permeability, scarring and possibly to the loss of fine-resolution central vision. Aflibercept acts as a soluble 'decoy' receptor that binds VEGF-A and PlGF and thereby inhibits the binding and activation of the VEGFR-1 and VEGFR-2 receptors.

Aflibercept is a recombinant fusion protein that incorporates portions of extracellular domains of the human VEGFR-1 (containing Ig-like C2-type 2 domain fragment; Uniprot: P17948|151-214|) and VEGFR-2 (containing Ig-like C2-type 3 domain fragment; Uniprot: P35968|224-320|) fused to the Fc portion of human immunoglobulin G1 (IgG1). Aflibercept is a dimeric glycoprotein with a protein molecular weight of 97 kDa (115 kDa with glycosylation).


>Aflibercept
SDTGRPFVEM YSEIPEIIHM TEGRELVIPC RVTSPNITVT LKKFPLDTLI PDGKRIIWDS
RKGFIISNAT YKEIGLLTCE ATVNGHLYKT NYLTHRQTNT IIDVVLSPSH GIELSVGEKL
VLNCTARTEL NVGIDFNWEY PSSKHQHKKL VNRDLKTQSG SEMKKFLSTL TIDGVTRSDQ
GLYTCAASSG LMTKKNSTFV RVHEKDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR
TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN
GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR DELTKNQVSL TCLVKGFYPS
DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH
YTQKSLSLSP G


Other therapies to treat AMD are available on the market and these include Verteporfin (ChEMBL: CHEMBL1200573; approved in 2000; trade name Visudyne), Pegaptanib sodium (ChEMBL: CHEMBL1201421; approved in 2004; trade name Macugen) and Ranibizumab (ChEMBL: CHEMBL1201825; approved on 2006; trade name Lucentis).

Aflibercept recommended dosage is 2 mg administrated by intravitreal (into the eye cavity) injection every 4 weeks for the first 12 weeks, followed by 2 mg via intravitreal injection once every 8 weeks.

Following intravitreal administration of 2 mg per eye, a fraction of the administrated dose binds to the endogenous VEGF in the eye to form the inactive Aflibercept:VEGF complex. Once absorbed into the systemic circulation, Aflibercept presents in the plasma as the free unbound Aflibercept and predominantly as the inactive Aflibercept:VEGF complex. Aflibercept has a volume of distribution (Vd) of 6 L and a terminal elimination half-life (t1/2) of 5 to 6 days after iv administration of doses of 2 to 4 mg.kg-1 of Aflibercept. Aflibercept undergoes elimination through both target-mediated disposition via binding to free endogenous VEGF and metabolism via proteolysis.

The full prescribing information for Eylea can be found here.

The license holder is Regeneron Pharmaceuticals, Inc. and the product website is www.eylea.com.

Comments

Popular posts from this blog

New SureChEMBL announcement

(Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f

A python client for accessing ChEMBL web services

Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d

LSH-based similarity search in MongoDB is faster than postgres cartridge.

TL;DR: In his excellent blog post , Matt Swain described the implementation of compound similarity searches in MongoDB . Unfortunately, Matt's approach had suboptimal ( polynomial ) time complexity with respect to decreasing similarity thresholds, which renders unsuitable for production environments. In this article, we improve on the method by enhancing it with Locality Sensitive Hashing algorithm, which significantly reduces query time and outperforms RDKit PostgreSQL cartridge . myChEMBL 21 - NoSQL edition    Given that NoSQL technologies applied to computational chemistry and cheminformatics are gaining traction and popularity, we decided to include a taster in future myChEMBL releases. Two especially appealing technologies are Neo4j and MongoDB . The former is a graph database and the latter is a BSON document storage. We would like to provide IPython notebook -based tutorials explaining how to use this software to deal with common cheminformatics p

Multi-task neural network on ChEMBL with PyTorch 1.0 and RDKit

  Update: KNIME protocol with the model available thanks to Greg Landrum. Update: New code to train the model and ONNX exported trained models available in github . The use and application of multi-task neural networks is growing rapidly in cheminformatics and drug discovery. Examples can be found in the following publications: - Deep Learning as an Opportunity in VirtualScreening - Massively Multitask Networks for Drug Discovery - Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set But what is a multi-task neural network? In short, it's a kind of neural network architecture that can optimise multiple classification/regression problems at the same time while taking advantage of their shared description. This blogpost gives a great overview of their architecture. All networks in references above implement the hard parameter sharing approach. So, having a set of activities relating targets and molecules we can tra

ChEMBL 26 Released

We are pleased to announce the release of ChEMBL_26 This version of the database, prepared on 10/01/2020 contains: 2,425,876 compound records 1,950,765 compounds (of which 1,940,733 have mol files) 15,996,368 activities 1,221,311 assays 13,377 targets 76,076 documents You can query the ChEMBL 26 data online via the ChEMBL Interface and you can also download the data from the ChEMBL FTP site . Please see ChEMBL_26 release notes for full details of all changes in this release. Changes since the last release: * Deposited Data Sets: CO-ADD antimicrobial screening data: Two new data sets have been included from the Community for Open Access Drug Discovery (CO-ADD). These data sets are screening of the NIH NCI Natural Product Set III in the CO-ADD assays (src_id = 40, Document ChEMBL_ID = CHEMBL4296183, DOI = 10.6019/CHEMBL4296183) and screening of the NIH NCI Diversity Set V in the CO-ADD assays (src_id = 40, Document ChEMBL_ID = CHEMBL4296182, DOI = 10.601